We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+31.61%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.19B
AUM Growth
+$204M
(+21%)
Cap. Flow
+$48.2M
Cap. Flow
% of AUM
4.04%
Top 10 Holdings %
Top 10 Hldgs %
41.65%
Holding
184
New
58
Increased
50
Reduced
24
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$22.4M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$14.4M |
| 3 |
ANI Pharmaceuticals
ANIP
|
+$13.8M |
| 4 |
BLUE
bluebird bio
BLUE
|
+$11.6M |
| 5 |
RLYP
RELYPSA INC COM
RLYP
|
+$11.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$24.3M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$18.9M |
| 3 |
Arrowhead Research
ARWR
|
+$18.4M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$14.7M |
| 5 |
HCA Healthcare
HCA
|
+$12.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.07% |
| 2 | Financials | 0.1% |
| 3 | Energy | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
JUNO
76
DELISTED
Juno Therapeutics, Inc.
JUNO
| $2.61M | 0.22% |
+50,000
| New | +$2.24M |
|
|
GNMX
77
DELISTED
Aevi Genomic Medicine Inc
GNMX
| $2.6M | 0.22% |
514,224
+459,151
| +834% | +$2.27M |
|
78
Vericel Corp
VCEL
$2.38B
| $2.58M | 0.22% |
850,000
-250,000
| -23% | -$712K |
|
|
SAGE
79
DELISTED
Sage Therapeutics
SAGE
| $2.58M | 0.22% |
70,484
-138,192
| -66% | -$5.15M |
|
80
Smith & Nephew
SNN
$13.7B
| $2.48M | 0.21% |
67,407
+34,999
| +108% | +$1.18M |
|
|
GNVC
81
DELISTED
GenVec, Inc.
GNVC
| $2.23M | 0.19% |
104,034
+22,034
| +27% | +$426K |
|
82
ProQR Therapeutics
PRQR
$244M
| $2.17M | 0.18% |
100,000
| – | – |
|
|
MGCD
83
DELISTED
MGC Diagnostics Corporation
MGCD
| $2.15M | 0.18% |
336,287
+8,799
| +3% | +$57.4K |
|
|
SHPG
84
DELISTED
Shire pic
SHPG
| $2.13M | 0.18% |
+10,000
| New | +$2.12M |
|
|
ALIM
85
DELISTED
Alimera Sciences
ALIM
| $2.12M | 0.18% |
+25,460
| New | +$2.07M |
|
86
PUT
Repligen
RGEN
$6.89B
| $1.98M | 0.17% |
+100,000
| New | +$2.24M |
|
|
ABMD
87
CALL
DELISTED
Abiomed Inc
ABMD
| $1.9M | 0.16% |
+50,000
| New | +$1.58M |
|
88
Celldex Therapeutics
CLDX
$2.94B
| $1.82M | 0.15% |
+6,667
| New | +$1.66M |
|
|
AGEN
89
Agenus
AGEN
$279M
| $1.6M | 0.13% |
+20,518
| New | +$1.26M |
|
|
UPI
90
DELISTED
UROPLASTY INC-NEW
UPI
| $1.58M | 0.13% |
766,349
+69,062
| +10% | +$164K |
|
|
WBA
91
DELISTED
Walgreens Boots Alliance
WBA
| $1.55M | 0.13% |
20,292
-29,708
| -59% | -$1.99M |
|
92
PUT
Vanda Pharmaceuticals
VNDA
$305M
| $1.43M | 0.12% |
100,000
-600,000
| -86% | -$7.1M |
|
|
ELOS
93
DELISTED
Syneron Medical Ltd
ELOS
| $1.42M | 0.12% |
152,609
+2,609
| +2% | +$25.2K |
|
|
ACHN
94
DELISTED
Achillion Pharmaceuticals
ACHN
| $1.3M | 0.11% |
106,100
-63,900
| -38% | -$780K |
|
95
EyePoint Inc
EYPT
$1.01B
| $1.29M | 0.11% |
+31,500
| New | +$1.26M |
|
|
GRCE
96
Grace Therapeutics
GRCE
$33.8M
| $1.29M | 0.11% |
5,362
| – | – |
|
|
VIRX
97
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $1.27M | 0.11% |
+2,381
| New | +$1.07M |
|
98
PUT
MannKind Corp
MNKD
$1.19B
| $1.04M | 0.09% |
40,000
| – | – |
|
99
Neurogene
NGNE
$665M
| $975K | 0.08% |
6,500
| – | – |
|
|
PARN
100
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
| $888K | 0.07% |
214,100
+4,100
| +2% | +$18.6K |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q4 2014 Portfolio in Review
As of Q4 2014, Perceptive Advisors held 184 positions worth $1.19B, up 21% from $988M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Perceptive Advisors deployed $48.2M of net new capital in Q4 2014, opening 58 new positions and adding to 50 existing holdings. Its largest new stake was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Energy.
On the sell side, the largest reduction was Celgene Corp, an estimated $24.3M trimmed.
- Perceptive Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.
- Perceptive Advisors added most to Amicus Therapeutics in Q4 2014, an estimated $14.4M increase.
- Perceptive Advisors's biggest Q4 2014 reduction was Celgene Corp, cutting an estimated $24.3M.
- Perceptive Advisors fully exited Arrowhead Research in Q4 2014, selling an estimated $18.4M.
- Perceptive Advisors's ten largest holdings make up 42% of its $1.19B portfolio in Q4 2014.
- Perceptive Advisors opened 58 new positions and closed 34 in Q4 2014.
- Perceptive Advisors's portfolio value rose 21% quarter-over-quarter to $1.19B.
Based on Perceptive Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.